• KOL
    • Dermatologic Adverse Events
    • Viswanath Reddy Belum
    • Viswanath Reddy Belum: Influence Statistics

      Viswanath Reddy Belum

      Viswanath Reddy Belum

      Wexner Medical Center at The Ohio State University, Columbus, OH, USA | Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, New York | Department of ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Viswanath Reddy Belum:Expert Impact

      Concepts for whichViswanath Reddy Belumhas direct influence:Dermatologic adverse events,Incidence risk,Sulfuric acid,Skin aging,Dermatological adverse events,Dermatologic aes,Nasal vestibulitis,Taxane chemotherapy.

      Viswanath Reddy Belum:KOL impact

      Concepts related to the work of other authors for whichfor which Viswanath Reddy Belum has influence:Immune checkpoint inhibitors,Skin toxicities,Alopecia areata,Cutaneous adverse events,Advanced melanoma,Antineoplastic agents,Nivolumab therapy.

      KOL Resume for Viswanath Reddy Belum

      Year
      2019

      Wexner Medical Center at The Ohio State University, Columbus, OH, USA

      2018

      Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, New York

      2017

      Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;

      2016

      Dermatology Service Department of Medicine, Memorial Sloan Kettering Cancer Center New York NY 10022 USA

      MSK 60th Street Outpatient Center, New York, NY;

      2015

      Memorial Sloan Kettering Cancer Center Dermatology Service Department of Medicine New York NY USA

      MSK 60th Street Outpatient Center, New York, NY

      2014

      Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY

      2013

      Dermatology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Rockefeller Outpatient Pavilion, Suite 228, 160 East 53rd St, 10022, New York, NY, USA

      Skin & VD Clinic, Hyderabad, AP, India

      2012

      Wexner Medical Center at The Ohio State University, 410 West 10th Ave, 43210, Columbus, OH, USA

      The Ohio State University, Columbus, OH

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Viswanath Reddy Belum is among the top experts in the world.
      Concept World rank
      risk hfsr #9
      Sign-in to see all concepts, it's free!

      Prominent publications by Viswanath Reddy Belum

      KOL-Index: 12200

      Background Regorafenib is a novel receptor tyrosine kinase inhibitor approved for use in metastatic colorectal cancer (mCRC) and locally advanced gastrointestinal stromal tumors (GISTs). The drug targets multiple receptors, including VEGF-R1/-R2/-R3, TIE-2, FGFR-1, PDGFR-α/β, KIT, RET, RAF, p38 MAPK. Adverse events include asthenia, hypertension, diarrhea, and hand-foot skin reaction (HFSR), with the latter representing one of the most clinically significant untoward events. The ...

      Known for Hfsr Regorafenib | Incidence Risk | Foot Skin | Mcrc Gist | Kinase Inhibitor
      KOL-Index: 10864

      BACKGROUND: Dermatologic adverse events (AEs) are some of the most frequently observed toxicities of immune-checkpoint inhibitor therapy, but they have received little attention. The drugs, pembrolizumab and nivolumab are recently approved inhibitors of the programmed death (PD)-1 receptor that have overlapping AE profiles however, the incidence, relative risk (RR), and clinico-morphological pattern of the associated dermatologic AEs are not known.

      METHODS: We conducted a systematic ...

      Known for Pembrolizumab Nivolumab | Dermatologic Adverse Events | Monoclonal Antibodies | 1 Receptor | Programmed Cell Death
      KOL-Index: 8149

      Cytotoxic T-lymphocyte-associated protein-4, programmed cell death protein and programmed cell death protein ligand 1 monoclonal antibodies (immune checkpoint inhibitors), are used to treat various malignancies. Their mechanism of action involves the inhibition of negative regulators of immune activation, resulting in immune-related adverse events (irAEs) including endocrinopathies, pneumonitis, colitis, hepatitis and dermatological events. Dermatological irAEs include maculopapular ...

      Known for Checkpoint Inhibitors | Alopecia Cancer Patients | Maculopapular Rash | Immunerelated Adverse Events | Monoclonal Antibodies
      KOL-Index: 5496

      BACKGROUND: Cabozantinib is approved in the treatment of progressive, metastatic medullary thyroid cancer (MTC). It is a small molecule inhibitor, which targets multiple receptors, including vascular endothelial growth factor receptor, tyrosine kinase with Ig and epidermal growth factor homology domains-2 and the proto-oncogenes MET (mesenchymal-epithelial transition factor) and RET (rearranged during transfection). The drug is currently in phase I/II/III clinical trials for a number of ...

      Known for Cabozantinib Treatment | Multikinase Inhibitor | Hand–foot Skin Reaction | Tyrosine Kinase | Adverse Event
      KOL-Index: 5182

      BACKGROUND: Oncologists treating patients with targeted therapies encounter adverse events (AEs) that pose management challenges, lead to dosing inconsistencies, and impact patient quality of life. Oncologists' practices and attitudes in the management of targeted therapy-related AEs in patients with renal cell carcinoma (RCC) are poorly understood. We sought to identify unmet needs associated with AE management and understand oncologists' treatment optimization strategies.

      METHODS: A ...

      Known for Renal Cell | Adverse Events Aes | Management Patients | Carcinoma Rcc | Kidney Neoplasms
      KOL-Index: 4718

      BackgroundThe mechanisms of skin aging have not been completely elucidated. Anecdotal data suggests that EGFR inhibition accelerates aging-like skin changes.ObjectiveThe objective of the study was to evaluate the clinical characteristics and investigate the cellular and molecular mechanisms underlying skin changes associated with the use of EFGRIs.Patients and methodsPatients during prolonged treatment with EGFRIs (>3 months) were analyzed for aging-like skin changes. Baseline EGFR ...

      Known for Skin Aging | Egfr Inhibitors | Erbb Receptors | Compared Young | Human Keratinocytes
      KOL-Index: 4360

      BACKGROUND: Many targeted therapies used in the treatment of cancer can lead to the development of xerosis, but the incidence and relative risk of xerosis have not been ascertained.

      OBJECTIVE: We conducted a systematic review and metaanalysis of clinical trials, to ascertain the incidence and risk of developing xerosis after taking anticancer drugs.

      METHODS: The PubMed (1966-October 2013), Web of Science (January 1998-October 2013), and American Society of Clinical Oncology abstracts ...

      Known for Targeted Anticancer | Incidence Risk | Antineoplastic Agents | Xerosis Patients | Skin Diseases
      KOL-Index: 4315

      BACKGROUND: The dermatologic adverse events (AEs) of various molecularly targeted therapies are well-described in adult cancer patients. Little has been reported on the incidence and clinical presentation of such AEs in pediatric patients with cancer. To address this gap, we analyzed the dermatologic AEs reported across clinical trials of targeted anticancer therapies in pediatric patients.

      PROCEDURES: We conducted an electronic literature search (PubMed, American Society of Clinical ...

      Known for Pediatric Patients | Dermatologic Adverse Events | Anticancer Therapies | Antineoplastic Agents | Molecular Targeted
      KOL-Index: 4256

      BACKGROUND: Peristomal dermatitis is a common complication for the >700 000 patients in the United States with an ostomy. The role of stoma skin care products in peristomal dermatitis is poorly understood.

      OBJECTIVE: To evaluate stoma skin care products as a cause of peristomal dermatitis.

      METHODS: A retrospective chart review of patients with peristomal dermatitis at four academic hospitals from January 2010 to March 2014 was performed. Patient demographics, clinical information and use ...

      Known for Contact Dermatitis | Patients Peristomal | Patch Test | Surgical Stomas | And Or
      KOL-Index: 4211

      Opinion statementRapid advances in drug discovery and the regulatory approval of a number of novel anticancer agents during the past decade pose unique challenges to the oncology community. While the benefits of such therapies receive most attention, adverse events (AEs), especially those pertaining to subspecialties (e.g., dermatology), often are underemphasized. To ensure best clinical outcomes, it would be important to bridge the gap between approval of a new drug and devising ...

      Known for Dermatologic Adverse Events | Monoclonal Antibodies | Phenylurea Compounds | Treatment Clinical | Humanized Antineoplastic
      KOL-Index: 4059

      Taxanes (docetaxel and paclitaxel) are among the most commonly prescribed anticancer drugs approved for the treatment of metastatic or locally advanced breast, non-small cell lung, prostate, gastric, head and neck, and ovarian cancers, as well as in the adjuvant setting for operable node-positive breast cancers. Although the true incidence of dermatological adverse events (AEs) in patients receiving taxanes is not known, and has never been prospectively analysed, they clearly represent ...

      Known for Taxane Chemotherapy | Dermatological Adverse Events | Antineoplastic Agents | Docetaxel Paclitaxel | Drug Eruptions
      KOL-Index: 4011

      The development of targeted therapies has ushered in a new era in the management of melanoma. Inhibitors of the RAS-RAF-MEK-ERK pathway have taken the center stage with development at a rapid pace. Vemurafenib was recently approved by regulatory agencies, and other agents (e.g. dabrafenib) are in various stages of clinical testing. These agents are producing remarkable results for patients, but are also presenting new challenges. Clinical toxicities and drug resistance are topmost ...

      Known for Braf Inhibitors | Cutaneous Toxicities | Vemurafenib Drug | Map Kinase | Dermatological Adverse
      KOL-Index: 3876

      IntroductionThe use of scalp cooling for the prevention of chemotherapy-induced alopecia (CIA) is increasing. Cold caps are placed onto the hair-bearing areas of the scalp for varying time periods before, during, and after cytotoxic chemotherapy. Although not yet reported, improper application procedures could result in adverse events (AEs). At present, there are no evidence-based scalp cooling protocols, and there is no regulatory oversight of their use.ObjectiveTo report the occurrence ...

      Known for Induced Alopecia | Hairbearing Areas | Scalp Cooling | Cold Caps | Humans Hypothermia
      KOL-Index: 3560

      Background and purposeCancer patients treated with targeted therapies (e.g., epidermal growth factor receptor inhibitors) are susceptible to dermatologic adverse events (AEs) including secondary skin infections. Whereas infections such as paronychia and cellulitis have been reported, nasal vestibulitis (NV) has not been described with the use of these agents. The aim of our study was to characterize NV in cancer patients treated with targeted therapies.MethodsWe utilized a retrospective ...

      Known for Nasal Vestibulitis | Female Humans Life | Staphylococcus Aureus | Dermatologic Adverse Events | Retrospective Chart Review
      KOL-Index: 3324

      BACKGROUND: The introduction of molecularly targeted anticancer therapies presents new challenges, among which dermatologic adverse events are noteworthy. Alopecia in particular is frequently reported, but the true incidence is not known.

      PATIENTS AND METHODS: We sought to ascertain the incidence and risk of developing alopecia during treatment with approved inhibitors of oncogenic pathways and molecules [anaplastic lymphoma kinase, breakpoint cluster region-abelson, B-rapidly ...

      Known for Approved Inhibitors | Mammalian Target | Dermatologic Adverse Events | Antineoplastic Agents | Alopecia Patients

      Key People For Dermatologic Adverse Events

      Top KOLs in the world
      #1
      Mario E Lacouture
      breast cancer dermatologic adverse events egfr inhibitors
      #2
      Caroline Robert
      advanced melanoma braf v600 advisory consultancy
      #3
      Dennis Paul West
      atopic dermatitis adverse drug events alopecia areata
      #4
      Milan J Anadkat
      egfr inhibitors dermatologic adverse events menadione topical lotion
      #5
      Yevgeniy Balagula
      dermatologic toxicities clinical presentation hsv infection
      #6
      Axel Hauschild
      metastatic melanoma advisory consultancy adjuvant treatment
      Select a search phrase   dermatologic adverse events

      Wexner Medical Center at The Ohio State University, Columbus, OH, USA | Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, New York | Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA | Dermatology

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.